Also known as: Crysvita
Crysvita (burosumab-twza) is an FDA-approved monoclonal antibody therapy for FGF23-mediated hypophosphatemic disorders, including X-linked hypophosphatemia and certain tumor-induced osteomalacia cases. It is administered subcutaneously and received initial U.S. approval in 2018. Current labeling includes pediatric and adult use with age thresholds depending on indication.
Ultragenyx began a restructuring plan that includes a 10% workforce reduction and termination of UX143 manufacturing agreements. The company also faces a class action tied to setrusumab disclosures.
Opus Genetics reported positive early data from its BEST1 gene therapy program and expects FDA action on its presbyopia treatment in October 2026. Ultragenyx announced 2025 revenue of $673 million and initiated a strategic restructuring plan targeting profitability in 2027.
Ultragenyx Pharmaceutical received an Incomplete Response Letter from the FDA for its UX111 gene therapy resubmission for Sanfilippo syndrome type A, requesting additional documentation. The company announced a 10% workforce reduction and expects profitability by 2027.
Ultragenyx reported Q4 2025 revenues of $207 million, up 25% year-over-year, while announcing a 10% workforce reduction and resubmission of its UX111 gene therapy application following positive long-term clinical data.
